Hats off to Icosavax, Inc. – $838m isn’t a bad payday for a company with a single clinical-stage candidate. The vaccine maker has been snapped up by AstraZeneca PLC, and the sizeable upfront payment shows how eager the UK giant is to enter the respiratory syncytial virus (RSV) space, where GSK and Pfizer precede it.
Key Takeways
- AstraZeneca has bought Icosavax for $838m upfront and potentially $1.1bn in total
AstraZeneca has structured the deal with the lion’s share of the money – $15 per share in cash – upfront....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?